Hepatitis B News and Research RSS Feed - Hepatitis B News and Research

Hepatitis B is one type of hepatitis – a liver disease- caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen or other body fluid. An infected woman can give hepatitis B to her baby at birth.

If you get HBV, you may feel as if you have the flu, or you may have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to scarring of the liver, liver failure or liver cancer.

There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine.
Vaccinations could have significant economic value

Vaccinations could have significant economic value

Vaccinations, long recognized as an excellent investment that saves lives and prevents illness, could have significant economic value that far exceeds their original cost, a new study from researchers at the Johns Hopkins Bloomberg School of Public Health has found. [More]
Experimental nanoparticle therapy shows promise for fighting primary liver cancer

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

An experimental nanoparticle therapy that combines low-density lipoproteins (LDL) and fish oil preferentially kills primary liver cancer cells without harming healthy cells, UT Southwestern Medical Center researchers report. [More]
World Hepatitis Alliance calls for comprehensive hepatitis strategies to help prevent liver cancer deaths

World Hepatitis Alliance calls for comprehensive hepatitis strategies to help prevent liver cancer deaths

Rock-icon David Bowie died recently at the age of 69 after a battle with what is being reported as liver cancer. Each year, more than 800,000 people die from liver cancer globally, the second biggest cancer killer. Yet, a high majority of these deaths are completely preventable. [More]
Cistus extracts attack HIV and Ebola viruses

Cistus extracts attack HIV and Ebola viruses

Scientists at the Helmholtz Zentrum München discover that extracts of the medicinal plant Cistus incanus (Ci) prevent human immunodeficiency viruses from infecting cells. Active antiviral ingredients in the extracts inhibit docking of viral proteins to cells. Antiviral activity of Cistus extracts also targets Ebola- and Marburg viruses. [More]
NJHA honors several individuals and organizations with Healthcare Leader Awards

NJHA honors several individuals and organizations with Healthcare Leader Awards

The New Jersey Hospital Association, the state's oldest and largest healthcare trade association, today held its annual awards program to honor several individuals and organizations for their commitment to the state's healthcare system and the patients and communities they serve. [More]
Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. [More]
FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. [More]
Monitoring HBcrAg levels could help optimise PEG-IFN therapy

Monitoring HBcrAg levels could help optimise PEG-IFN therapy

Serum hepatitis B core-related antigen could serve as a quantitative marker of response to pegylated interferon therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen (HBeAg), findings indicate. [More]
Rescue TDF monotherapy effective in multidrug resistant chronic HBV

Rescue TDF monotherapy effective in multidrug resistant chronic HBV

Researchers from the Republic of Korea say that rescue therapy with tenofovir disoproxil fumarate alone is an appropriate option for patients with multidrug resistant chronic hepatitis B virus infection. [More]
STAT4 variant predicts HBV IFNα response

STAT4 variant predicts HBV IFNα response

Variation in the STAT4 gene is associated with response to interferon (IFN)α therapy in patients with hepatitis B e antigen-positive chronic hepatitis B virus infection, suggests research published in Hepatology. [More]
Only 17.4% of nurses comply with all nine standard precautions for infection prevention

Only 17.4% of nurses comply with all nine standard precautions for infection prevention

Only 17.4 percent of ambulatory care nurses reported compliance in all nine standard precautions for infection prevention, according to a study published in the January issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology. [More]
Study outlines new model to help predict age-related response to hepatitis B vaccine

Study outlines new model to help predict age-related response to hepatitis B vaccine

Physicians have known for years that patients respond differently to vaccines as they age. There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine. [More]
Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

In results published on October 19, 2015 in the Journal of Lipid Research, a team of translational scientists at the Medical University of South Carolina report a new reason why non-alcoholic steatohepatitis (NASH) worsens in people who are obese. [More]
Estrogen helps women fight flu virus better than men

Estrogen helps women fight flu virus better than men

Estrogen dramatically reduced the amount of flu virus that replicated in infected cells from women but not from men, a new study by researchers at the Johns Hopkins Bloomberg School of Public Health shows. [More]
Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine. [More]
Estrogen may protect women against flu

Estrogen may protect women against flu

The female sex hormone estrogen has anti-viral effects against the influenza A virus, commonly known as the flu, a new study in American Journal of Physiology—Lung Cellular and Molecular Physiology reports. [More]
Inflammation associated with elevated glutamate in the brain could guide depression treatments

Inflammation associated with elevated glutamate in the brain could guide depression treatments

Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine. [More]
Pre-existing nutritional deficits, immune dysfunction may increase hepatitis E risk during pregnancy

Pre-existing nutritional deficits, immune dysfunction may increase hepatitis E risk during pregnancy

Researchers from the Johns Hopkins Bloomberg School of Public Health have found a link between pre-existing nutritional deficits and immune dysfunction and the risk of hepatitis E infection during pregnancy. [More]

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection. [More]
GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease. [More]
Advertisement
Advertisement